tradingkey.logo

Regulus Therapeutics' stock price doubles on Novartis's buyout offer

ReutersApr 30, 2025 11:44 AM

Shares of Regulus Therapeutics RGLS.O more than double to $7.79 premarket

Novartis offers to buy Regulus for $7/shr cash upfront and another $7/shr on hitting certain regulatory milestones for kidney disease drug farabursen

Offer worth $800 mln on upfront price

RGLS shares have already more than doubled this year through last close

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI